Novo Nordisk Expands Legal Battle Over Cheaper Weight Loss Drug Versions

Novo Nordisk has expanded its legal battle against vendors selling cheaper compounded versions of its medication semaglutide, marketed as Wegovy for obesity treatment. The company has filed 14 new lawsuits against vendors selling compounded semaglutide, which is a cheaper alternative to the medication. This move comes after digital weight-loss company Noom launched a service offering compounded semaglutide at a lower cost. Novo Nordisk argues that compounded semaglutide is not approved by regulatory authorities and can be dangerous for patients.

Novo Nordisk has taken significant legal action to protect patients from the risks associated with unapproved compounded versions of its medication semaglutide, marketed as Wegovy for obesity treatment. The company has filed 14 new lawsuits against vendors selling compounded semaglutide, which is a cheaper alternative to the medication. This move comes after digital weight-loss company Noom launched a service offering compounded semaglutide at a lower cost.

Novo Nordisk argues that compounded semaglutide is not approved by regulatory authorities and can be dangerous for patients. The company has been proactive in addressing the issue, filing over 130 lawsuits across 40 states and securing 44 permanent injunctions against defendants involved in illegal marketing and selling of knockoff Wegovy and Ozempic.

The legal actions are directed at organizations involved in illegal activities, including violating laws prohibiting the corporate practice of medicine, interfering with doctors' decisions, and steering patients toward unapproved knockoff drugs under the false guise of personalization. The lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded "semaglutide" under the false guise of personalized medicine.

The FDA has issued multiple alerts warning about the dangers of these knockoff drugs, including reports of patients overdosing by mistakenly administering five to 20 times the intended dose and requiring hospitalization. Independent data underscores the dangers posed by compounded semaglutide products, with many relying on synthetic API imported from facilities in China that lack FDA oversight or quality controls.

Novo Nordisk has launched educational campaigns and created a resource website, semaglutide.com, to raise awareness about the risks of unapproved knockoffs and ensure patients can access authentic, FDA-approved treatments. With all doses of Wegovy and Ozempic available nationwide, the company continues to explore new channels to meet patients where they receive care, ensuring they can access safe, effective treatments under the supervision of licensed healthcare professionals.

References:
[1] https://www.morningstar.com/news/pr-newswire/20250805ny44906/novo-nordisk-expands-legal-action-to-protect-us-patients-from-unsafe-non-fda-approved-compounded-semaglutide
[2] https://www.everydayhealth.com/diet-nutrition-products/glp-1s-online/